Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "Hypertension"

133 News Found

Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg
Drug Approval | February 27, 2023

Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.


Zydus receives tentative approval from USFDA for Bosentan tablets for oral suspension
Drug Approval | February 16, 2023

Zydus receives tentative approval from USFDA for Bosentan tablets for oral suspension

Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022)


JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23
News | February 09, 2023

JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23

Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%


Need a paradigm shift for popularising ayurveda in India
News | February 07, 2023

Need a paradigm shift for popularising ayurveda in India

For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions


Lupin launches Sacubitril and Valsartan combination drug for heart failure patients
News | January 19, 2023

Lupin launches Sacubitril and Valsartan combination drug for heart failure patients

Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure


Eye-Q inaugurates its new facility in Yamunanagar
Healthcare | December 30, 2022

Eye-Q inaugurates its new facility in Yamunanagar

The new facility will be able to handle four times as many patients as the previous facility.


Zydus receives final approval and 180 days shared exclusivity from USFDA for Selexipag Tablets
Drug Approval | December 23, 2022

Zydus receives final approval and 180 days shared exclusivity from USFDA for Selexipag Tablets

Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH


JB Pharma to buy Glenmark's ‘Razel’ for Rs. 314 crore in India and Nepal
News | December 14, 2022

JB Pharma to buy Glenmark's ‘Razel’ for Rs. 314 crore in India and Nepal

The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy


AstraZeneca’s Dapagliflozin receives CDSCO approval
Drug Approval | November 30, 2022

AstraZeneca’s Dapagliflozin receives CDSCO approval

Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD


Alembic receives USFDA final approval for Nifedipine Extended-Release Tablets
Drug Approval | November 22, 2022

Alembic receives USFDA final approval for Nifedipine Extended-Release Tablets

Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022